Members   Providers   Employers   Forms   Prescription Drugs   What to do When

Medical Review - Experimental/Investigational

Radioimmunotherapy for Non-Hodgkin’s Lymphoma with Tositumomab (Bexxar®)

DESCRIPTION
Tositumomab (Bexxar®) is antineoplastic monoclonal antibodies that is FDA approved for use in select patients with non-Hodgkin’s lymphoma.

POLICY
The use of tositumomab (Bexxar®) for the initial treatment of non-Hodgkin's Lymphoma is considered experimental/investigational

CPT CODING
G3001

Determined by the Medical Director on February 14, 2006 reference source Anthem Blue Cross and Blue Shield medical policy RAD.00031.

(Web updated 6/2006)

- Back -